166 related articles for article (PubMed ID: 19430980)
1. Efficacy and safety of prolonged immunomodulatory treatment with interferon beta.
Demina TL; Khachanova NV; Davydovskaya MV; Popova NF; Gusev EI
Neurosci Behav Physiol; 2009 Jun; 39(5):497-9. PubMed ID: 19430980
[No Abstract] [Full Text] [Related]
2. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
Demina TL; Khachanova NV; Davydovskaia MV; Popova NF; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):24-6. PubMed ID: 18567192
[No Abstract] [Full Text] [Related]
3. Interferon beta-1a and beta-1b for treatment of multiple sclerosis.
Benatar M
Lancet; 2002 Nov; 360(9343):1428; author reply 1428-9. PubMed ID: 12424021
[No Abstract] [Full Text] [Related]
4. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
5. Experiences with interferon-beta-1b treatment in MS after three year follow-up.
Bencsik K; Rajda C; Füvesi J; Járdánházy T; Török M; Vécsei L
Swiss Med Wkly; 2002 May; 132(17-18):237. PubMed ID: 12087490
[No Abstract] [Full Text] [Related]
6. Introduction.
Owens GM
J Manag Care Pharm; 2013; 19(1 Suppl A):S3. PubMed ID: 23383727
[No Abstract] [Full Text] [Related]
7. Intramuscular interferon beta-1a and evolving treatment options and outcomes measurement for MS: considerations for managed care.
Barnes CJ; Caon C; Foley JF; Friedman M; Menzin J; Nair KV; Nichols C; Olvey EL; Owens GM; Pill MW; Skrepnek GH; White LA; Zerkowski K
J Manag Care Pharm; 2013; 19(1 Suppl A):S1-53. PubMed ID: 23383730
[No Abstract] [Full Text] [Related]
8. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.
Tremlett HL; Oger J
Neurology; 2003 Aug; 61(4):551-4. PubMed ID: 12939437
[TBL] [Abstract][Full Text] [Related]
9. [Interferon therapy of multiple sclerosis. A question of the correct dose?].
Hohlfeld R
Nervenarzt; 2001 Feb; 72(2):67-8. PubMed ID: 11256156
[No Abstract] [Full Text] [Related]
10. [Interferons beta in patients with multiple sclerosis].
Vlasov IaV; Kuznetsova NI; Poverennova IE; Khivintseva EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):54-5. PubMed ID: 16117149
[No Abstract] [Full Text] [Related]
11. [Report from the Satellite Symposium: Leading the way: outstanding efficacy of interferon beta-1b right from the start. Berlin, Germany, 06.24.2002].
Cendrowski W
Neurol Neurochir Pol; 2002; 36(6):1260-3. PubMed ID: 12715704
[No Abstract] [Full Text] [Related]
12. Treat early, but treat hard: Interferon-beta dose makes a difference.
Mikol DD
J Neuroophthalmol; 2001 Dec; 21(4):237-9. PubMed ID: 11756850
[No Abstract] [Full Text] [Related]
13. [10 years of interferon treatment in multiple sclerosis. Does the future belong to high-dose therapy?].
MMW Fortschr Med; 2003 May; 145 Suppl 2():108. PubMed ID: 14579501
[No Abstract] [Full Text] [Related]
14. Multiple sclerosis and interferon beta-1b, past, present and future.
Horowski R
Clin Neurol Neurosurg; 2002 Jul; 104(3):259-64. PubMed ID: 12127665
[No Abstract] [Full Text] [Related]
15. [About the article: "Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis" by Jacobs LD et al].
Labetouelle M
J Fr Ophtalmol; 2001 Feb; 24(2):222. PubMed ID: 11332406
[No Abstract] [Full Text] [Related]
16. Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis.
Chofflon M; Ben-Amor AF
Clin Neurol Neurosurg; 2002 Jul; 104(3):244-8. PubMed ID: 12127662
[No Abstract] [Full Text] [Related]
17. [The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis].
Popova EV; Boĭko AN; Davydovskaia MV; Demina TL; Kukel' TM; Lashch NIu; Popova NF; Khachanova NV; Shchur SG; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(10 Pt 2):93-6. PubMed ID: 24300821
[TBL] [Abstract][Full Text] [Related]
18. Treatment of multiple sclerosis with interferon beta-1 b.
Abdul-Ahad A; Shah S; Galazka A
Neurology; 1997 Aug; 49(2):641-2. PubMed ID: 9270626
[No Abstract] [Full Text] [Related]
19. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
Nikfar S; Rahimi R; Abdollahi M
Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
[TBL] [Abstract][Full Text] [Related]
20. [PRISMS study. Interferon beta-1a therapy in relapsing-remitting multiple sclerosis].
Limmroth V
Internist (Berl); 2001 Feb; 42(2):305-7. PubMed ID: 11244885
[No Abstract] [Full Text] [Related]
[Next] [New Search]